2023 iwCLL Program Agenda

**AGENDA topics and times subject to change** As of 04/20/23
Friday, October 6
7:30 AM
YIM Continental Breakfast
8:00 AM
Young Investigator Meeting
6:00 PM
iwCLL Welcome Reception
Saturday, October 7, 2023
7:15 AM
Continental Breakfast
8:15 AM
Welcome and Introductions
Jennifer Brown, MD, PhD
8:30 AM
In Memoriam and Celebrating 20 Years of iwCLL
Theme 1: Pathogenesis of CLL
Session 1: Integrative Aspects of Genomics
8:40 AM
Multiomic Integration in CLL
8:55 AM
Whole-Genome Analysis of CLL and Interplay of Coding, Non-Coding, Transcriptome and Epigenetic Events
Pauline Robbe
9:10 AM
Genomics of Richter’s Transformation: Part I
Ferran Nadeu
9:20 AM
Genomics of Richter’s Transformation: Part II
Erin Parry
formatting off
9:30 AM
Commentary on Each Other’s Work and Consensus Regarding the Genomics of Richter’s Transformation
Ferran Nadeu and Erin Parry
9:40 AM
Panel Discussion With Interactivity and Audience Q&A
9:50 AM
Oral and Poster Abstracts
10:10 AM
Morning Break
Session 2: Proteomics and Metabolism of CLL
10:35 AM
Proteogenomic Characterization of CLL and Drug Response/Resistance
Sascha Dietrich
10:50 AM
CLL Proteomics and Immunoproteomics
Cathy Wu, MD
11:05 AM
Cancer Metabolism
TBD
Matthew Vander Heiden
11:20 AM
Panel Discussion With Interactivity and Audience Q&A
11:35 AM
Oral and Poster Abstracts
12:55 PM
LUNCH / Industry Supported Symposium
Session 3: Microenvironment and Pre-Clinical Immunotherapies
1:55 PM
Anti-Tumor Immunity in the Lymphoid Microenvironment
Martina Seiffert
2:10 PM
The Tumor Supportive Microenvironment of CLL
Jerome Paggetti
2:25 PM
Modeling the Tumor Microenvironment of CLL
Christina Scielzo
2:35 PM
The Tumor Microenvironment and Genetic Heterogeneity of CLL
Clare Sun
2:45 PM
Panel Discussion With Interactivity and Audience Q&A
3:05 PM
Oral and Poster Abstracts
3:25 PM
Afternoon Break
3:50 PM
Keynote
Session 4: Debate and Roundtable – How Do We Define Success in CLL?
4:20 PM
Multiparty “Statement of Perspective”
4:55 PM
Panel Discussion With Interactivity and Audience Q&A
5:30 PM
Oral and Poster Abstracts
End of Day 1
Sunday, October 8
7:00 AM
Industry Supported Symposium
7:15 AM
Continental Breakfast
7:30 AM
Modeling the Tumor Microenvironment of CLL
Theme 2: Therapy of CLL
Session 5: Optimizing Initial Therapy of CLL
8:15 AM
The Role Today of Continuous BTK Inhibitors
Kerry Rogers, MD
8:30 AM
Updated Perspective on Time-Limited Venetoclax + Obintuzumab
Othman Al-Sawaf
8:45 AM
Current and Future Use of BTKi + BCL-2i Combinations
Nitin Jain
9:00 AM
Panel Discussion With Interactivity and Audience Q&A
9:15 AM
Trials in Progress
9:35 AM
Oral and Poster Abstracts
9:55 AM
Morning Break
10:20 AM
Industry Supported Symposium
Session 6: Mechanisms of Resistance
11:20 AM
Resistance to Covalent BTKi
Adrien Wiestner, MD, PhD
11:35 AM
Resistance to Non-Covalent BTKi
Varsha Gandhi, MD
11:50 AM
Resistance to BCL2i
Rachel Thijssen
12:05 PM
Panel Discussion With Interactivity and Audience Q&A
Theme: “Targeted Strategies to Overcome Resistance”
12:20 PM
Oral and Poster Abstracts
12:55 PM
LUNCH / Industry Supported Symposium
Session 7: Future Directions for the Treatment of Relapsed/Refractory CLL
2:30 PM
BTK Degraders – From Bench To Bedside
Alexey Danilov
2:40 PM
Novel Inducers of Apoptosis
Deepa Sampath
2:50 PM
How to Overcome T-Cell Dysfunction: Bispecifics
Arnon Kater, MD, PhD
3:00 PM
How to Overcome T-Cell Dysfunction: Cellular Therapies
Jos Melenhorst
3:10 PM
Panel Discussion with Interactivity and Audience Q&A
3:25 PM
Trials in Progress
3:45 PM
Oral and Poster Abstracts
4:05 PM
Binet/Rai Medal Presentation
3:25 PM
Adjourn
End of Day 2
Monday, October 9
7:00 AM
Industry Supported Symposium
7:15 AM
Continental Breakfast
Session 8: Richter’s Transformation – From Biology to Clinic
8:15 AM
In Vivo Modeling of CLL Transformation
Silvia Deaglio, MD, PhD
8:25 AM
In Vivo Modeling of CLL Transformation: Multiplex In Vivo CRISPR Editing
Elisa Ten Hacken
8:35 AM
In Vivo Modeling of CLL Transformation: TP53 and CDKN2a/b Model
Dimitar Efremov
8:45 AM
Panel Discussion on In Vivo Modeling
8:55 AM
Chemoimmunotherapy and BCR-Targeted Agents for Richter’s Transformation
Sameer Parikh, MBBS
9:05 AM
Investigational Therapies for Richter’s Transformation: Bispecifics
Philip Thompson, BA, BSW, MSW, PhD
9:15 AM
Investigational Therapies for Richter’s Transformation: Cellular Therapies
Tanya Siddiqi
9:25 AM
Panel Discussion with Interactivity and Audience Q&A
9:35 AM
Oral and Poster Abstracts
9:55 AM
Morning Break
Session 9: Immunodeficiency and Infections in Patients with CLL
10:20 AM
CLL Vaccine Responsiveness
Chris Pleyer
10:35 AM
What Can We Learn from COVID About Immune Dysfunction and Risk of Infections in CLL?
Yair Herishanu
10:50 AM
General Management of CLL patients from a Vaccine and Prophylaxis Standpoint
Carolyn Owen
11:05 AM
Panel Discussion with Interactivity and Audience Q&A Theme: “How Infections and Immunity Impact Selection of Therapy”
11:20 AM
Oral and Poster Abstracts
11:40 AM
Industry Supported Symposium
12:40 PM
LUNCH

Session 10: Global Perspective on CLL Management – Real World Data and Patient Experiences

1:30 PM
The Impact of the War on Management of Patients with CLL in Ukraine: What can the iwCLL do to Mitigate Impact in Short and Longer Term
Iryna Kryachok
1:40 PM
Managing Patients with CLL from Different Socio-Economic Backgrounds in Argentina
Miguel Pavlovsky
1:50PM
Update on the iwCLL Capacity Building Pilot Program in Tanzania
William Frank Mawalla
2:00 PM
Challenges of Diagnosis and Management of Patients with CLL in South Korea
Ja Min Byun
2:10 PM
Trial Updates from China
Shenmiao Yang
2:20 PM
Panel Discussion With Interactivity and Audience Q&A
2:40 PM
Afternoon Break
Session 11: Past, Present, and Future of CLL
3:05 PM
TBD
3:20 PM
Remaining Unmet Needs in the Care of CLL
3:35 PM
Role of the iwCLL Going Forward
3:50 PM
Panel Discussion With Interactivity and Audience Q&A
4:10 PM
Closing Comments/iwCLL 2023 Awards/2025 Announcement
4:25 PM
Close of Workshop